As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Source
No articles found.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
Histogenics historically focused on the development of restorative cell therapies,...
Histogenics historically focused on the develop...
LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...
LogicBio is a Cambridge, MA-based genome editin...
Join the National Investor Network and get the latest information with your interests in mind.